▶ Manufacturer: Ilhwa Co., Ltd.
▶ Sold by: Ilhwa Co., Ltd.
▶ Insurance code : A06502241
▶ Storage : Airtight container, store at room temperature (1 to 30℃)
Green oblong tablet
Glimepiride 2mg
1. Single therapy
1) Initial dose and dose determination
For patients never administered this drug previously, begin administration with 1mg glimepiride once a day. Increase dose by 1mg at intervals of 1 to 2 weeks if needed. Glimepiride as a single drug has almost no additional benefits when administered at a dose of 4mg or higher, but some patients exhibited better metabolic regulation when dose was increased to 6mg (or 8mg). If administration of 4mg a day fails, first consider switching to insulin therapy. If not, consider concomitant use with insulin or other oral diabetes medications.
2) Second dose adjustment
As therapy progresses, improved regulation of diabetes may reduce the amount of this drug necessary. Therefore it may be necessary to stop administration of this drug or to reduce the dose to avoid hypoglycemia. Dose adjustments should also be considered in the event of weight loss, change in lifestyle, or other factors that may increase the risk of hypoglycemia or hyperglycemia.
This drug is administered as a supplement to dietary and exercise therapy to improve blood glucose regulation in Type II diabetes patients.
1. This drug is administered in single therapy.
2. This drug may be administered concomitantly in the following cases.
1) Concomitant administration with insulin if oral hypoglycemics do not provide adequate blood glucose regulation
2) Concomitant administration of this drug with metformin if single therapy with sulfonylurea or metformin does not provide adequate blood glucose regulationGreen oblong tablet
Glimepiride 2mg
1. Single therapy
1) Initial dose and dose determination
For patients never administered this drug previously, begin administration with 1mg glimepiride once a day. Increase dose by 1mg at intervals of 1 to 2 weeks if needed. Glimepiride as a single drug has almost no additional benefits when administered at a dose of 4mg or higher, but some patients exhibited better metabolic regulation when dose was increased to 6mg (or 8mg). If administration of 4mg a day fails, first consider switching to insulin therapy. If not, consider concomitant use with insulin or other oral diabetes medications.
2) Second dose adjustment
As therapy progresses, improved regulation of diabetes may reduce the amount of this drug necessary. Therefore it may be necessary to stop administration of this drug or to reduce the dose to avoid hypoglycemia. Dose adjustments should also be considered in the event of weight loss, change in lifestyle, or other factors that may increase the risk of hypoglycemia or hyperglycemia.
This drug is administered as a supplement to dietary and exercise therapy to improve blood glucose regulation in Type II diabetes patients.
1. This drug is administered in single therapy.
2. This drug may be administered concomitantly in the following cases.
1) Concomitant administration with insulin if oral hypoglycemics do not provide adequate blood glucose regulation
2) Concomitant administration of this drug with metformin if single therapy with sulfonylurea or metformin does not provide adequate blood glucose regulation
